A Two‐for‐One Bargain: Using Cilnidipine to Treat Hypertension and Its Comorbidities

Iyer, Rugmani Padmanabhan; Lindsey, Merry L.; Chilton, Robert

doi:10.1111/jch.12112

Cited by 7 publications

(3 citation statements)

References 17 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study, for the first time, demonstrates that an SPC of cilnidipine, a unique L‐/N‐type CCB, and valsartan lowered MHBP and MHPP progressively and for a longer period in patients with uncontrolled hypertension, especially those with increased MHPR, than in those without increased MHPR. These findings were more evident, especially in the patients with wide MHPP, which suggested that the preserved sympatholytic characteristics of cilnidipine in the SPC of Cil/Val would be clinically more effective for the reduction of MHBP and arterial stiffness in patients with uncontrolled hypertension with stiffened arteries and sympathetic hyperactivity.…”

Section: Discussionmentioning

confidence: 63%

Single‐pill combination of cilnidipine, an L‐/N‐type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE‐Combi survey

Kario

Matsuda

Nagahama

et al. 2020

J of Clinical Hypertension

View full text Add to dashboard Cite

The home blood pressure (BP) control by a single‐pill combination of cilnidipine (an L‐/N‐type calcium channel blocker; CCB) and valsartan (HOPE‐Combi) survey is a multicenter, post‐marketing, prospective observational study of a single‐pill combination of cilnidipine 10 mg and valsartan 80 mg (SPC of Cil/Val) in patients with uncontrolled hypertension. We examined the effects of the SPC of Cil/Val on morning home systolic BP (MHSBP) and morning home pulse pressure (MHPP) of 1036 patients with hypertension over 12 months. MHSBP decreased by 14.0 mm Hg (P < .01), and MHPP decreased by 6.6 mm Hg (P < .01). Moreover, morning home pulse rate (MHPR) decreased by 2.1 bpm (P < .01). A more progressive and greater decrease in MHSBP (−17.2 vs −10.3 mm Hg, P < .01) and MHPP (−7.6 vs −4.9 mm Hg, P < .01) was observed in patients with higher MHPR (≥70 bpm) than in those with lower MHPR (<70 bpm) over the treatment period. In particular, in patients with a wide MHPP (≥70 mm Hg), the difference in the MHPP reduction was greater in patients with higher MHPR than in those with lower MHPR (−17.9 vs −13.6 mm Hg, P < .01). These results suggested that the SPC of Cil/Val, which possesses the unique sympatholytic characteristics of an L‐/N‐type CCB, was particularly effective in patients with uncontrolled hypertension and sympathetic hyperactivity.

show abstract

Section: Discussionmentioning

confidence: 63%

Single‐pill combination of cilnidipine, an L‐/N‐type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE‐Combi survey

Kario

Matsuda

Nagahama

et al. 2020

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…Blockade of entry of Ca+2 leads to inhibition of vasoconstriction cascade, eventually resulting in vasodilatation. It helps to decrease peripheral resistance and, therefore, blood pressure [9,10]. It also acts on N-type calcium channels present at the neuronal terminals [11].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Estimation of Azilsartan and Cilnidipine in Bulk by Rp-HPLC and Assessment of Its Applicability in Marketed Tablet Dosage Form

Andhale¹,

Nikalje

2022

Int J App Pharm

View full text Add to dashboard Cite

Objective: This study aims to build up the RP-HPLC process for Azilsartan and Cilnidipine and authenticate the RP-HPLC process according to ICH validation code Q2R1. Methods: System suitability testing was performed to discover the qualifying criterion of the method by injecting the identical standard solution of Azilsartan 40μg/ml and Cilnidipine 10μg/ml in mixture/combination in subsequent optimized chromatographic conditions and the chromatogram was recorded. Moreover, the planned method was validated as per ICH guideline Q2R1 for the following parameters: linearity and range, precision, accuracy, robustness, and determined % recovery. Results: The outcomes of %RSD for retention time and peak area were found to be 0.65 and 1.32 for Azilsartan and 0.85 and 1.90 for Cilnidipine. The correlation coefficient, y-intercept, slope of the regression line were 0.9996,-1127.1, 3313.9, and 0.9993, 1460.2, 2876.4 for Azilsartan and Cilnidipine, respectively. Moreover, the range of this method was observed to be 40-240μg/ml and 10-60 μg/ml for Azilsartan and Cilnidipine, standard concentrations respectively. The % RSD achieved for precision (repeatability) was observed in the range of 1.57 to 2.43 for Azilsartan and 0.70 to 1.88 for Cilnidipine. The % accuracy was found in the range of 96.96 to 101.92% w/w for Azilsartan and 99.19 to101.96%w/w for Cilnidipine. The percent recovery values achieved for Azilsartan were in the range of 99.87 to 106.39% w/w and for Cilnidipine in the range of 94.51 to 105.96% w/w. Conclusion: The author concludes that the simultaneous estimation of Azilsartan and Cilnidipine with predefined objectives was successfully achieved. Moreover, the method was found to be steadfast for the quantification of Azilsartan and Cilnidipine in marketed tablet dosage forms.

show abstract

“…National and international guidelines recommend angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, and beta-blockers for the management of hypertension. CCBs are among the most used antihypertensive medications currently in the market, and the use of CCBs is especially effective for the treatment of hypertension in the elderly who frequently have large-vessel stiffness [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials

Chakraborty¹,

Langade²,

More³

et al. 2021

Cureus

View full text Add to dashboard Cite

Introduction: Hypertension is one of the most common cardiovascular diseases, and the prevalence of hypertension continues to rise across the globe. National and international guidelines recommend angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, and beta-blockers for the management of hypertension. CCBs are among the most used antihypertensive medications and Cilnidipine is a newer dihydropyridine CCB shown to have a prolonged antihypertensive property. Objective: This meta-analysis of comparative randomized and non-randomized clinical trials evaluated the effect of Cilnidipine monotherapy or combination therapy on systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate (PR) over 48 weeks of therapy. Study design: PubMed (MEDLINE) and Google scholar databases were searched to identify studies designed to evaluate the effects of Cilnidipine in the treatment of hypertensive patients. The study criteria for inclusion into the meta-analysis were all prospective, randomized, and non-randomized clinical studies published till March 2021, studies published in a peer-reviewed journal, the inclusion of patients with hypertension, assessment of blood pressure and heart rate, and a follow-up of four weeks or longer. The initial search identified 82 potential articles; of these, 24 met the inclusion criteria. Studies with <4 weeks treatment period and those not having a CCB were excluded. Outcomes: Change in SBP, DBP, and PR from baseline at the end of therapy compared between the Cilnidipine and other CCB's. Results: Cilnidipine caused a significant reduction (p<0.05) in SBP, DBP, and PR at end of therapy, whereas the reduction in SBP, DBP, and PR with Cilnidipine was similar to other CCB's (p>0.05). The results of this meta-analysis revealed that there were no significant differences in the efficacy in the treatment of hypertensive patients with Cilnidipine and the other therapies. Conclusion: Cilnidipine has similar anti-hypertensive effects compared with other first-line antihypertensive drugs commonly used in practice. We recommend Cilnidipine as a novel first-line CCB for the management of hypertension either as a monotherapy or as a combination therapy.

show abstract

A Two‐for‐One Bargain: Using Cilnidipine to Treat Hypertension and Its Comorbidities

Cited by 7 publications

References 17 publications

Single‐pill combination of cilnidipine, an L‐/N‐type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE‐Combi survey

Single‐pill combination of cilnidipine, an L‐/N‐type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE‐Combi survey

Simultaneous Estimation of Azilsartan and Cilnidipine in Bulk by Rp-HPLC and Assessment of Its Applicability in Marketed Tablet Dosage Form

Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials

Contact Info

Product

Resources

About